Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation

Biochemical Journal

Volumn 452, Issue 2, 2013, Pages 331-343

  Meyer, Daniela ^a   Sielaff, Frank ^a   Hammami, Maya ^a   Böttcher Friebertshäuser, Eva ^a   Garten, Wolfgang ^a   Steinmetzer, Torsten ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Influenza virus; Protease inhibitor; Synthetic substrate; Transmembrane serine proteinase 2 (TMPRSS2); Type II transmembrane serine protease (TTSP)

Indexed keywords

PHENYLALANINE DERIVATIVE; PROTEINASE INHIBITOR; SERINE PROTEINASE; TRANSMEMBRANE SERINE PROTEINASE 2; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN;

ARTICLE; CATALYSIS; CYTOTOXICITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME STRUCTURE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN METAPNEUMOVIRUS; INFLUENZA VIRUS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SARS CORONAVIRUS; VIRUS ACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CELL LINE; DRUG DESIGN; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VIRUS ACTIVATION;

EID: 84877763765     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20130101     Document Type: Article

References (58)

1. Paoloni-Giacobino, A., Chen, H., Peitsch, M. C., Rossier, C. and Antonarakis, S. E. (1997) Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 44, 309-320
2. Netzel-Arnett, S., Hooper, J. D., Szabo, R., Madison, E. L., Quigley, J. P., Bugge, T. H. and Antalis, T. M. (2003) Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 22, 237-258
3. Szabo, R. and Bugge, T. H. (2008) Type II transmembrane serine proteases in development and disease. Int. J. Biochem. Cell Biol. 40, 1297-1316
4. Szabo, R., Wu, Q., Dickson, R. B., Netzel-Arnett, S., Antalis, T. M. and Bugge, T. H. (2003) Type II transmembrane serine proteases. Thromb. Haemostasis 90, 185-193
5. Afar, D. E., Vivanco, I., Hubert, R. S., Kuo, J., Chen, E., Saffran, D. C., Raitano, A. B. and Jakobovits, A. (2001) Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61, 1686-1692
6. Lin, B., Ferguson, C., White, J. T., Wang, S., Vessella, R., True, L. D., Hood, L. and Nelson, P. S. (1999) Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180-4184
7. Chen, Y. W., Lee, M. S., Lucht, A., Chou, F. P., Huang, W., Havighurst, T. C., Kim, K., Wang, J. K., Antalis, T. M., Johnson, M. D. and Lin, C. Y. (2010) TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am. J. Pathol. 176, 2986-2996
8. Kim, T. S., Heinlein, C., Hackman, R. C. and Nelson, P. S. (2006) Phenotypic analysis of mice lacking the TMPRSS2-encoded protease. Mol. Cell. Biol. 26, 965-975
9. Wilson, S., Greer, B., Hooper, J., Zijlstra, A., Walker, B., Quigley, J. and Hawthorne, S. (2005) The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem. J. 388, 967-972
10. Taubenberger, J. K. and Morens, D. M. (2010) Influenza: the once and future pandemic. Public Health Rep. 125 (Suppl. 3), 16-26
11. Böttcher, E., Matrosovich, T., Beyerle, M., Klenk, H. D., Garten, W. and Matrosovich, M. (2006) Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 80, 9896-9898
12. Klenk, H. D. and Garten, W. (1994) Host cell proteases controlling virus pathogenicity. Trends Microbiol. 2, 39-43
13. Böttcher-Friebertshäuser, E., Freuer, C., Sielaff, F., Schmidt, S., Eickmann, M., Uhlendorff, J., Steinmetzer, T., Klenk, H. D. and Garten, W. (2010) Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J. Virol. 84, 5605-5614
14. Schowalter, R. M., Smith, S. E. and Dutch, R. E. (2006) Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH. J. Virol. 80, 10931-10941
15. Shirogane, Y., Takeda, M., Iwasaki, M., Ishiguro, N., Takeuchi, H., Nakatsu, Y., Tahara, M., Kikuta, H. and Yanagi, Y. (2008) Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J. Virol. 82, 8942-8946
16. Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M. and Taguchi, F. (2010) Efficient activation of SARS coronavirus spike protein by the transmembrane protease, TMPRSS2. J. Virol. 84, 12658-12664
17. Glowacka, I., Bertram, S., Müller, M. A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gnirss, K. et al. (2011) Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 85, 4122-4134
18. Shulla, A., Heald-Sargent, T., Subramanya, G., Zhao, J., Perlman, S. and Gallagher, T. (2011) A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 85, 873-882
19. Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F. and Matsuyama, S. (2012) Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Virol. 86, 6537-6545
20. Rao, N. V. and Hoidal, J. R. (2012) Epitheliasin. In Handbook of Proteolytic Enzymes (Rawlings, N. D. and Salvesen, G. S., eds), pp. 3003-3007, Elsevier, Amsterdam
21. Böttcher, E., Freuer, C., Steinmetzer, T., Klenk, H. D. and Garten, W. (2009) MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 27, 6324-6329
22. Zhirnov, O. P., Klenk, H. D. and Wright, P. F. (2011) Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res. 92, 27-36
23. Steinmetzer, T., Schweinitz, A., Stürzebecher, A., Dönnecke, D., Uhland, K., Schuster, O., Steinmetzer, P., Müller, F., Friedrich, R., Than, M. E. et al. (2006) Secondary amides of sulfonylated 3- amidinophenylalanine. New potent and selective inhibitors of matriptase. J. Med. Chem. 49, 4116-4126
24. Dixon, M. (1953) The determination of enzyme inhibitor constants. Biochem. J. 55, 170-171
25. Becker, G. L., Sielaff, F., Than, M. E., Lindberg, I., Routhier, S., Day, R., Lu, Y., Garten, W. and Steinmetzer, T. (2010) Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J. Med. Chem. 53, 1067-1075
26. Sisay, M. T., Steinmetzer, T., Stirnberg, M., Maurer, E., Hammami, M., Bajorath, J. and Gütschow, M. (2010) Identification of the first low-molecular-weight inhibitors of matriptase-2. J. Med. Chem. 53, 5523-5535
27. Schweinitz, A., Steinmetzer, T., Banke, I. J., Arlt, M. J., Stürzebecher, A., Schuster, O., Geissler, A., Giersiefen, H., Zeslawska, E., Jacob, U. et al. (2004) Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J. Biol. Chem. 279, 33613-33622
28. Schweinitz, A., Stürzebecher, A., Stürzebecher, U., Schuster, O., Stürzebecher, J. and Steinmetzer, T. (2006) New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1. Med. Chem. 2, 349-361
29. Nara, M., Terashima, S. and Yamada, S. (1980) Stereochemical studies LVII: synthesis of optically-active compounds by the novel use of meso-compounds. 1. Efficient synthesis of 2 structural types of optically pure prostaglandin intermediates. Tetrahedron 36, 3161-3170
30. Böttcher-Friebertshäuser, E., Stein, D. A., Klenk, H. D. and Garten, W. (2011) Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. J. Virol. 85, 1554-1562
31. Bender, M. L., Begue-Canton, M. L., Blakeley, R. L., Brubacher, L. J., Feder, J., Gunter, C. R., Kezdy, F. J., Killheffer, Jr, J. V., Marshall, T. H., Miller, C. G. et al. (1966) The determination of the concentration of hydrolytic enzyme solutions: α-chymotrypsin, trypsin, papain, elastase, subtilisin, and acetylcholinesterase. J. Am. Chem. Soc. 88, 5890-5913
32. Knight, C. G. (1995) Active-site titration of peptidases. Methods Enzymol. 248, 85-101
33. Jameson, G. W., Roberts, D. V., Adams, R. W., Kyle, W. S. and Elmore, D. T. (1973) Determination of the operational molarity of solutions of bovine α-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem. J. 131, 107-117
34. Wiley, M. R., Chirgadze, N. Y., Clawson, D. K., Craft, T. J., Gifford-Moore, D. S., Jones, N. D., Olkowski, J. L., Weir, L. C. and Smith, G. F. (1996) D-Phe-Pro-p-amidinobenzylamine: a potent and highly selective thrombin inhibitor. Bioorg. Med. Chem. Lett. 6, 2387-2392
35. Gustafsson, D., Antonsson, T., Bylund, R., Eriksson, U., Gyzander, E., Nilsson, I., Elg, M., Mattsson, C., Deinum, J., Pehrsson, S. et al. (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemostasis 79, 110-118
36. Stürzebecher, J., Prasa, D., Hauptmann, J., Vieweg, H. and Wikström, P. (1997) Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J. Med. Chem. 40, 3091-3099
37. Stürzebecher, J., Vieweg, H., Steinmetzer, T., Schweinitz, A., Stubbs, M. T., Renatus, M. and Wikström, P. (1999) 3-Amidinophenylalanine- based inhibitors of urokinase. Bioorg. Med. Chem. Lett. 9, 3147-3152
38. Sielaff, F., Böttcher-Friebertshäuser, E., Meyer, D., Saupe, S. M., Volk, I. M., Garten, W. and Steinmetzer, T. (2011) Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg. Med. Chem. Lett. 21, 4860-4864
39. Biela, A., Sielaff, F., Terwesten, F., Heine, A., Steinmetzer, T. and Klebe, G. (2012) Ligand binding stepwise disrupts water network in thrombin: enthalpic and entropic changes reveal classical hydrophobic effect. J. Med. Chem. 55, 6094-6110
40. Stürzebecher, A., Dönnecke, D., Schweinitz, A., Schuster, O., Steinmetzer, P., Stürzebecher, U., Kotthaus, J., Clement, B., Stürzebecher, J. and Steinmetzer, T. (2007) Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2. ChemMedChem 2, 1043-1053
41. Tucker, T. J., Lumma, W. C., Mulichak, A. M., Chen, Z., Naylor-Olsen, A. M., Lewis, S. D., Lucas, R., Freidinger, R. M. and Kuo, L. C. (1997) Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J. Med. Chem. 40, 830-832
42. Künzel, S., Schweinitz, A., Reissmann, S., Stürzebecher, J. and Steinmetzer, T. (2002) 4-Amidinobenzylamine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. 12, 645-648
43. Shiraishi, T., Kadono, S., Haramura, M., Kodama, H., Ono, Y., Iikura, H., Esaki, T., Koga, T., Hattori, K., Watanabe, Y. et al. (2008) Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination. Bioorg. Med. Chem. Lett. 18, 4533-4537
44. Saupe, S. M. and Steinmetzer, T. (2012) A new strategy for the development of highly potent and selective plasmin inhibitors. J. Med. Chem. 55, 1171-1180
45. Lumma, Jr, W. C., Witherup, K. M., Tucker, T. J., Brady, S. F., Sisko, J. T., Naylor-Olsen, A. M., Lewis, S. D., Lucas, B. J. and Vacca, J. P. (1998) Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J. Med. Chem. 41, 1011-1013
46. Rittle, K. E., Barrow, J. C., Cutrona, K. J., Glass, K. L., Krueger, J. A., Kuo, L. C., Lewis, S. D., Lucas, B. J., McMasters, D. R., Morrissette, M. M. et al. (2003) Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position. Bioorg. Med. Chem. Lett. 13, 3477-3482
47. Dönnecke, D., Schweinitz, A., Stürzebecher, A., Steinmetzer, P., Schuster, M., Stürzebecher, U., Nicklisch, S., Stürzebecher, J. and Steinmetzer, T. (2007) From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Bioorg. Med. Chem. Lett. 17, 3322-3329
48. Stürzebecher, J., Prasa, D., Wikström, P. and Vieweg, H. (1995) Structure-activity relationships of inhibitors derived from 3-amidinophenylalanine. J. Enzyme Inhib. 9, 87-99
49. Hammami, M., Rühmann, E., Maurer, E., Heine, A., Gütschow, M., Klebe, G. and Steinmetzer, T. (2012) New 3-amidinophenylalanine-derived inhibitors of matriptase. MedChemComm 3, 807-813
50. Steinmetzer, T., Dönnecke, D., Korsonewski, M., Neuwirth, C., Steinmetzer, P., Schulze, A., Saupe, S. M. and Schweinitz, A. (2009) Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors. Bioorg. Med. Chem. Lett. 19, 67-73
51. Garten, W. and Klenk, H. D. (2008) Cleavage activation of the influenza virus hemagglutinin and its role in pathogenesis. In Avian Influenza (Klenk, H. D., Matrosovich, M. and Stech, J., eds), pp. 156-167, Karger, Basel
52. Bertram, S., Glowacka, I., Müller, M. A., Lavender, H., Gnirss, K., Nehlmeier, I., Niemeyer, D., He, Y., Simmons, G., Drosten, C. et al. (2011) Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J. Virol. 85, 13363-13372
53. Antoniak, S., Pawlinski, R. and Mackman, N. (2011) Protease-activated receptors and myocardial infarction. IUBMB Life 63, 383-389
54. Gustafsson, D., Bylund, R., Antonsson, T., Nilsson, I., Nystrom, J. E., Eriksson, U., Bredberg, U. and Teger-Nilsson, A. C. (2004) A new oral anticoagulant: the 50-year challenge. Nat. Rev. Drug Discovery 3, 649-659
55. Hellstern, P., Stürzebecher, U., Wuchold, B., Haubelt, H., Seyfert, U. T., Bauer, M., Vogt, A. and Stürzebecher, J. (2007) Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of Factor Xa and thrombin. J. Thromb. Haemostasis 5, 2119-2126
56. Matter, H., Nazare, M., Gussregen, S., Will, D. W., Schreuder, H., Bauer, A., Urmann, M., Ritter, K., Wagner, M. and Wehner, V. (2009) Evidence for C-Cl/C-Br . . . pi interactions as an important contribution to protein-ligand binding affinity. Angew. Chem., Int. Ed. Engl. 48, 2911-2916
57. Katz, B. A., Sprengeler, P. A., Luong, C., Verner, E., Elrod, K., Kirtley, M., Janc, J., Spencer, J. R., Breitenbucher, J. G., Hui, H. et al. (2001) Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chem. Biol. 8, 1107-1121
58. Ettmayer, P., Amidon, G. L., Clement, B. and Testa, B. (2004) Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47, 2393-2404